GUILDFORD, UK / ACCESSWIRE / November 9, 2023 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) diagnostic solutions for use in ...
More than two years after an initial FDA approval in melanoma, Bristol Myers Squibb is moving its PD-1/LAG-3 combo Opdualag into registrational testing in one of the most important oncology disease ...
IPS is a multimodal biomarker that combines known and novel clinical and immune-related biomarkers from DNA and RNA analysis to predict a patient's response to ICI-based therapy. The new clinical ...
A high PD-L1 score suggested immunotherapy, yet cisplatin chemotherapy was chosen, raising questions about treatment decisions. The patient experienced severe side effects from chemotherapy, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results